IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) In Vitro IV-361 has less inhibition on CDK2 (K i ≥1000 nM) or PLK1 (K i ≥5000 nM). IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC 50 ≤100 nM) in periphery blood mononuclear cell (PBMC). IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI 50 ≤100 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CDK7 ≤50 nM (Ki) CDK2 ≥1000 nM (Ki)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
IV-361
CAS number：2055741-39-2 molecular formula：C23H32FN5O2Si
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2055741-39-2 | molecular formula | C23H32FN5O2Si |
| molecular weight | 457.62 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
